IL6 and Alzheimer disease: 24-week, prospective, randomized, open-controlled study, in subjects with mild-to-moderate Alzheimer’s disease in association with T2DM. Outcome measures: ADAS-JCog, MMSE, TNFα, IL-6, C-reactive protein.